The United States Food and Drug Administration (FDA) has approved Arexvy, the first respiratory syncytial virus vaccine, for use in women during pregnancy to protect the baby.
This vaccine has been developed by Pfizer.
It is approved for use in women between 32 and 36 weeks of pregnancy to prevent lower respiratory tract infections and severe illness in infants up to six months of age.
The vaccine developer has stated that a large number of hospitalizations due to RSVV could be prevented by maternal vaccination.
People suffering from this disease are affected by infection of the lungs and respiratory tract. It is highly common in children and the elderly. It is generally most affected during the winter months.
Most people infected with RSV develop only cold-like symptoms, such as runny nose, loss of appetite, coughing and sneezing. Mild infections usually get better without medical treatment.
